Pharma News

Testosterone therapy can help the elderly suffering from low testosterone levels and pre-existing heart condition reduce their risks of stroke, heart attacks and death, researchers report.

A single dose of oxytocin nasal spray, known to cut food intake, can lower impulsive behaviour in overweight and obese men, say researchers.Oxytocin nasal spray is a synthetic version of the hormone oxytocin which is important for controlling food intake and weight.

People with type 1 diabetes are three times more prone to the risk of developing epilepsy later in life, finds a new research.The findings revealed that in patients with type 1 diabetes, the risk of developing epilepsy a neurological disorder was significantly higher than that in patients without the disease.

The AYUSH healthcare system is the key to a healthy population, union minister Shripad Naik said on Friday."The goal of achieving a healthy population can be met through AYUSH (Ayurveda, Yoga and Naturopathy, Unani, Siddha and Homoeopathy) system," the minister of state for AYUSH and health and family welfare said.

The National Human Rights Commission on Friday issued notices to the commerce and health ministries over reports that India has reassured the US-India Business Council to take a restrained approach in handing out licences to produce cheaper versions of drugs patented with the American firms.

The British Medical Journal (BMJ) in its latest issue has called for radical reforms of the Medical Council of India (MCI) which, it said, failed to oversee quality and integrity in health services in the country.

Corbus Pharmaceuticals Holdings Inc. announced that a protocol amendment has been added to one of the Company's existing Investigational New Drug ("IND") Application with the U.S. Food and Drug Administration ("FDA") for a Phase 2 clinical trial of Resunab in systemic lupus erythematosus ("SLE").

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the conditional approval of Pandemic Live Attenuated Influenza Vaccine (P/LAIV). P/LAIV is indicated for the prevention of influenza in an officially declared pandemic in children and adolescents from 12 months to less than 18 years of age.

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo)  announced that the company has filed an application for the manufacture and sales in Japan of hydromorphone hydrochloride oral formulation (extended-release and immediate-release formulations), a narcotic analgesic.

[adsense:336x280:8701650588]

Janssen-Cilag International NV announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a Positive Opinion recommending marketing authorisation in the European Union for the medicinal product TREVICTA® (paliperidone palmitate a 3 monthly injection) for the maintenance treatment of schizophrenia. If approved, this 3 monthly injection will allow patients to maintain an optimal level of treatment in their blood with fewer administrations, compared to currently available antipsychotic treatments, and therefore may improve outcomes for patients, carers and HCPs.1 A 1 monthly formulation of paliperidone palmitate (XEPLION®) is approved for the maintenance treatment of schizophrenia in Europe.